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Abstract
L-SIGN is a C-type lectin expressed on liver sinusoidal endothelial cells involved in the capture of hepatitis C virus and trans-infection of
adjacent hepatocyte cells. The neck region of L-SIGN is highly polymorphic, with three to nine tandem repeats of 23 residues. This
polymorphism is associated with a number of infectious diseases, but has not been explored in HCV. We therefore investigated the impact
of L-SIGN neck region length variation on the outcome of HCV infection. We studied 322 subjects, 150 patients with persistent HCV
infection, 63 individuals with spontaneous clearance and 109 healthy controls. In healthy subjects, we found a total of nine genotypes, with
the 7/7 genotype being the most frequent (33%) followed by the 7/6 (22.9%) and the 7/5 (18.3%). The frequencies of the alleles were as
follows: 7-LSIGN (56.4%), 6-LSIGN (20.2%), 5-L-SIGN (18.3%) and 4-L-SIGN (5%). The frequency of the 7/4 genotype was higher in
spontaneous resolvers (14.3%) as compared with the persistent group (4%) (OR = 0.25, 95% CI = 0.07–0.82, p 0.022). In addition, we
found that 4-L-SIGN was associated with spontaneous resolution of HCV infection (OR = 0.30, 95%CI, 0.12–0.74, p 0.005). Interestingly,
patients with 4-L-SIGN had lower viral loads when compared with carriers of the 5 (p 0.001), 6 (p 0.021) and 7-alleles (p 0.048). The results
indicate that neck region polymorphism of L-SIGN can inﬂuence the outcome of HCV infection and the four-tandem repeat is associated
with clearance of HCV infection.
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Introduction
Chronic hepatitis C virus (HCV) infection is a leading cause of
end-stage liver disease, including liver cirrhosis and hepato-
cellular carcinoma (HCC), with 170 million of the world’s
population infected [1,2]. Spontaneous eradication of the virus
is achieved in only 15–50% of newly infected individuals, while
the rest develop chronic infection [2]. The ability of the virus
to persist within a host is attributed to its efﬁcient ability to
evade the adaptive and innate components of the host’s
immune system [3,4]. Liver-lymph node-speciﬁc ICAM-3-
grabbing integrin (L- SIGN), also known as dendritic cell-
speciﬁc intracellular adhesion molecular-3-grabbing noninte-
grin related (DC-SIGNR or CD209L), is a C-type lectin
expressed on endothelial cells in the liver and lymph node
sinusoids, and might promote spread of viruses that target liver
and lymph nodes [5–7]. Several studies have demonstrated
that L-SIGN binds soluble HCV E2 and mediates trans-infection
of liver cells by HCV pseudoparticles (HCVpp) [8–12]. Thus it
may concentrate HCV in the liver and enable captured virus to
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cross the endothelial barrier, thereby facilitating infection of
adjacent hepatocytes [9,13]. These ﬁndings raise the hypoth-
esis that interaction of HCV with this molecule in liver and
lymph nodes may have important consequences for HCV
infection [9].
L-SIGN is a type II transmembrane protein composed of
three domains: an N-terminal cytoplasmic domain, a neck
region made up of a highly polymorphic domain, and a C-
terminal extracellular C-type carbohydrate recognition
domain (CRD) involved in pathogen binding [5]. The neck
region is responsible for the homo-oligomerization that brings
the CRDs into proximity for high-afﬁnity ligand binding [14].
The L-SIGN gene, located on chromosome 19p13, is highly
polymorphic in the neck region based on the number of
repeats in exon 4. There are between three and nine repeats
(3- to 9- alleles) of a 69-base-pair segment [5,15,16]. Each
repeat encodes a hydrophobic motif characterized by a-helical
coiled coils [14,15]. Disease association studies have shown
that polymorphism of the L-SIGN repeat region is associated
with protection against SARS coronavirus infection [17] and
also HIV infection [18,19]. The high expression levels of
L-SIGN on hepatic sinusoidal endothelial cells suggests it may
be involved in the capture and concentration of HCV in the
liver and hence the establishment of persistent infection [8,20].
In addition, in vitro studies have shown that length variation in
the L-SIGN neck region could inﬂuence the establishment of
HCV infection [20]. To our knowledge, the association
between L-SIGN neck region length polymorphism and
spontaneous clearance of HCV has not been explored. In this
study, we tested the hypothesis that this variant may be
associated with persistent/spontaneous clearance of HCV
infection in a Moroccan population that has been well
characterized in terms of the natural outcome of HCV
infection.
Material and Methods
Study population
After giving written informed consent for genetic testing,
every participant was interviewed and completed a structured
questionnaire on demographic data and selected risk factors.
The study protocol was evaluated and approved by the Ethics
Committee of the Faculty of Medicine of Casablanca and the
study was conducted in accordance with the ethical guidelines
of the 1975 Declaration of Helsinki as reﬂected in a priori
approval by the institution’s human research committee. A
total of 322 Moroccan subjects were enrolled in this study.
Blood samples from chronic hepatitis C patients and individ-
uals with spontaneous clearance were collected at the
Medical Center of Biology at the Pasteur Institute of Morocco
and Service of Medicine B CHU Ibn Rochd Hospital,
Casablanca, from November 2010 to September 2012. One
hundred and ﬁfty patients had persistent HCV infection (90
women, 60 men), among them 40 patients with cirrhosis
according to ﬁbrosis stage. All subjects were persistently
positive for anti-hepatitis C virus (anti-HCV) antibodies and
HCV ribonucleic acid (HCV-RNA) over a period of more
than 6 months. Sixty-three individuals had spontaneously
resolved HCV infection (45 women, 18 men). All were
positive for HCV-speciﬁc antibodies and negative for serum
HCV RNA by qRT-PCR from at least two measurements
more than 6 months apart. To obtain information on the
frequency of alleles in the Moroccan population, a set of 109
unrelated anti-HCV and HBsAg-negative healthy subjects (56
women, 53 men) of mixed Berberic and Arabic ethnicity, with
normal serum levels of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST), were recruited from the
Pasteur Institute of Morocco. All patients were HBsAg and
HIV negative.
Serological markers for HBsAg, anti-HCV and anti-HIV
were tested with commercially available kits (Axsym, Abbott
Diagnostics, Wiesbaden-Delkenheim, Germany, and Gen-
screen Ag/Ab HIV Ultra, Biorad, Marnes La Coquette, France).
Plasma HCV-RNA was measured using COBAS AmpliPrep/
COBAS TaqMan (Roche Diagnostics, Mannheim, Germany).
Genotyping of HCV was determined by PCR-sequencing as
described previously [21].
Genotyping of L-SIGN neck region length polymorphism
The genomic DNA samples were obtained from peripheral
whole blood using the QIAamp Blood kit (Qiagen, CA, USA)
according to the manufacturer’s protocols. Genomic DNA
concentration was assessed using a NanoVue spectrophotom-
eter (GE Healthcare, Freiburg, Germany) and adjusted to
10 ng/lL in H20.
The L-SIGN repeat region in exon 4 was ampliﬁed from
genomic DNA with the following pair of primers: L32: 5′-
CCACTTTAGGGCAGGAC-3′ and L28: 5′-AGCAAA CTCA-
CACCACA AA-3′, as reported previously [5,16]. PCR was
carried out in a ﬁnal volume of 25 lL, containing 50 ng of
genomic DNA, 20 pmol/lL of each primer, 0.5 units of
Platinum Taq DNA Polymerase (Invitrogen, Foster City, CA,
USA), 200 lM of each dNTP and 1.5 mM MgCl2. The cycle
conditions were 5 min at 94°C followed by 30 cycles of 5 s at
95°C, 1 min at 70°C, and then a single cycle of 10 min at 72°C.
Allele 9 yielded 716 bp, allele 8 yielded 647 bp, allele 7 yielded
578 bp, allele 6 yielded 509 bp, allele 5 yielded 440 bp, allele 4
yielded 371 bp and allele 3 yielded 302 bp PCR products.
Alleles products were resolved on 3% agarose gel and
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ethidium-bromide staining. For 30% of the samples, PCR was
repeated to ensure reproducibility of the assay. The results of
the PCRs were 100% concordant.
Genotyping for rs12979860 was performed as described
previously [22] by using a TaqMan 5′ allelic discrimination assay
custom-designed primers and probes as follows: forward primer
TGCCTGTCGTGTACTGAACCA-3′ and reverse 5′-GAGC
GCGGAGTGCAATTC-3′, and probes TGGTTCGCGCCTTC
(VIC) andCTGGTTCACGCCTTC (FAM) (Applied Biosystems,
Foster City, CA, USA). The genotype of each sample was
analysed by using SDS 1.1 software for allelic discrimination
(ABI7000, Applied Biosystems).
Statistical analysis
Comparisons of continuous variables between groups were
assessed with the Mann–Whitney U-test and a post hoc
correction for multiple comparisons was made for an ANOVA
test. For categorical variables the v2 test or Fischer’s exact test
was used. Allele and genotype frequencies were obtained by
direct counting. Departures from Hardy–Weinberg equilib-
rium (HWE) were determined by comparing the observed
genotype frequencies with expected genotype frequencies
using Arelquin software. The Fisher’s exact test or v2 test was
used to determine differences in allele/genotype frequencies. A
p value of <0.05 was considered statistically signiﬁcant. All
tests were two-sided. Logistic regression was performed using
the multinomial logistic regression analysis tool of SPSS v20.
Only genotypes represented in both groups were included in
the analysis and the 7/7 genotype or 7/7 and C/C genotypes
were used as the reference group.
Results
Table 1 illustrates the main demographic and clinical charac-
teristics. There were no signiﬁcant differences between groups
in terms of age and gender (p >0.05). As shown in Table 2,
overall, the most common genotype in our population was 7/
7 (33%), followed by 7/6 (22.9%) and 7/5 (18.3%). Allele 7 has
the highest frequency at 56.4%, followed by allele 6 at 20.2%,
allele 5 at 18.3% and allele 4 at 5%. The genotype frequencies in
the control population did not deviate from the Hardy-
Weinberg equilibrium (p 0.315).
We next examined whether the frequency distributions of
L-SIGN neck region genotypes and alleles were signiﬁcantly
different between the HCV-infected and resolved groups.
Logistic regression analysis of the association of genotype with
outcome demonstrated that the 7/4 genotype was the only
genotype signiﬁcantly associated with resolution of HCV
(p 0.022, OR = 0.25, 95% CI = 0.07–0.82) (Table 2). The 7/
4 genotype frequency was over-represented in the resolved
group (14.3%) as compared with the chronic patients (4%)
(p 0.015) (Table 3).
A previous study showed that the medium length 6- or 7-
tandem repeats form a rigid neck region that projects the
CRDs away from the membrane, ensuring strong multivalent
adhesion to the target membrane, thus promoting the access
to pathogens [23]. Therefore, we grouped these alleles and the
frequency of 6/6 + 7/6 + 7/7 genotypes as higher in the
chronic group (82/150, 54.7%) than the spontaneous resolvers
(24/61, 39.3%) (OR = 1.86, 95% CI = 0.97–3.57, p 0.04)
(Table 2).
As for allelic frequencies, we found that allele 4 was
associated with spontaneous clearance of HCV infection
(OR = 0.30, 95% CI = 0.12–0.74). Analysis between sponta-
neous clearance group with allele 4 and chronic patients group
showed that this allele is most prevalent in the spontaneous
subjects (11.1% vs. 3.7%, respectively, p 0.005).
In order to explore the contribution of L-SIGN neck region
polymorphism to HCV replication and necroinﬂammatory
activity, we analysed viral loads in infected cases according to
the various L-SIGN alleles (Fig. 1a). Patients carrying allele 4-
had lower viral loads (median = 121 266 UI/mL) than patients
with allele 5- (median = 862 317 UI/mL) (p 0.001), allele 6-
(median = 842 000 UI/mL) (p 0.021) and allele 7- (median =
785 324 UI/mL) (p 0.048). In contrast, no signiﬁcant correla-
tion was found between L-SIGN alleles and mean ALT (Fig. 1b,
p >0.05) or AST levels (Fig. 1c, p >0.05). To test the
association between the L-SIGN variants and liver damage,
we genotyped this polymorphism in 40 patients with cirrhosis
then compared them with 109 healthy subjects. The distribu-
tion of allelic frequencies was not signiﬁcant between patients
and healthy subjects (Fig. 1d, p >0.05).
In addition, when chronic HCV patients were stratiﬁed by
their viral genotypes, the frequencies of L-SIGN genotypes
were not different between patients with genotype 1 (G-1) and
patients with genotype 2 (G-2) (Fig. 2a).
Finally, we checked the response of patients with shorter
and longer tandem repeat to PegIFN-a plus RBV treatment.
TABLE 1. Demographic and clinical characteristics of the
study subjects
Chronic
hepatitis C
(n = 150)
Spontaneous
clearance
(n = 63)
Healthy
controls
(n = 109)
Mean age  SD, years 63.09  12.06 59.81  12.81 56.45  10.86
Gender (male/female) 60/90 18/45 53/56
ALT (IU/L) 74.96  43.10 29.81  14.61 27.49  6.02
AST (IU/L) 77.25  6.11 29.11  18.36 25.21  9.37
Median viral load (IU/mL) 868 500
HCV genotype 1/2 99/51
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We analysed this polymorphism with viral clearance after
treatment in patients infected with genotype 1b. Frequencies
of 4-, 5-, 6- and 7- were 4%, 12%, 48% and 35% in In non-
responders group and were 8%, 15%, 46% and 31% in
sustained virological response (SVR) group, respectively
(p >0.05) (Fig. 2b).
Given that L-SIGN and IL28B genes are located on chromo-
some 19, we hypothesized that clearance could be detected
when favourable genotypes are combined in a given subject.
Consequently, statistical gene–gene interactions between the
L-SIGN and IL28B polymorphisms were examined (Table 3).
We observed that cleared subjects carrying the 7/4 genotype
had a higher frequency of the IL28B-CC genotype than chronic
patients (12.7% vs. 2%, p 0.003). Further, a signiﬁcant spon-
taneous clearance of HCV infection among L-SIGN 7/4 and
IL28B-CC genotype carriers with OR of 0.21 (95% CI = 0.04–
TABLE 2. L-SIGN neck-region polymorphism among Moroccan healthy controls, spontaneous clearance subjects and the HCV-
infected group
Moroccan healthy
group (n = 109) (%)
Spontaneous
clearance (n = 63) (%)
Chronic hepatitis
C (n = 150) (%)
Spontaneous clearance vs.
chronic hepatitis C
OR (95%CI) p-value (Pc)
Genotypes
4/4 2 (1.8) 1 (1.6) 0 (0) na 1.000
5/4 1 (0.9) 1 (1.6) 2 (1.3) 0.74 (0.06–8.77) 0.809
6/4 0 (0) 2 (3.1) 3 (2) 0.55 (0.08–3.66) 0.539
7/4 6 (5.5) 9 (14.3) 6 (4) 0.25 (0.07–0.82) 0.022 (0.264)
5/5 7 (6.4) 2 (3.1) 4 (2.7) 0.74(0.12–4.48) 0.740
6/5 5 (4.6) 7 (11.1) 23 (15.3) 1.21 (0.42–3.44) 0.720
7/5 20 (18.3) 16 (25.4) 28 (18.7) 0.65 (0.27–1.54) 0.321
8/5 0 (0) 0 (0) 1 (0.7) na 1.000
6/6 7 (6.9) 4 (6.3) 15 (10) 1.38 (0.39–4.88) 0.616
7/6 25 (22.9) 7 (11.1) 29 (19.3) 1.53 (0.54–4.27) 0.420
7/7 36 (33) 14 (22.2) 38 (25.3) 1.00
9/7 0 (0) 0 (0) 1 (0.7) na 1.000
Homozygotes 52 (47.7) 21 (33) 57 (38)
Heterozygotes 57 (52.3) 42 (67) 93 (62)
n = 218 n = 126 n = 300
L-SIGN alleles
4 11 (5) 14 (11.1%) 11 (3.7) 0.30 (0.12–0.74) 0.005 (0.030)
5 40 (18.3) 28 (22.2%) 62 (20.7) 0.91 (0.53–1.56) 0.795
6 44 (20.2) 24 (19%) 85 (28.3) 1.68 (0.98–2.89) 0.052
7 123 (56.4) 60 (47.7%) 140 (46.7) 0.96 (0.62–1.49) 0.915
8 0 (0) 0 (0%) 1 (0.3) na 1.000
9 0 (0) 0 (0%) 1 (0.3) na 1.000
na, not applicable.
Pc, Bonferroni correction was applied.
TABLE 3. Risk of chronicity for combinations of L-SIGN and IL28B genotypes
L-SIGN
polymorphism
IL28B
rs12979860
Chronic hepatitis C
(n = 150)
Spontaneous clearance
(n = 63) OR (95%CI) p-value
7/7 CC 14 (9.3%) 8 (12.7%) 1.00
7/7 CT 10 (6.7%) 3 (4.8%) 1.93 (0.40–9.02) 0.413
7/7 TT 14 (9.3%) 3 (4.8%) 2.67 (0.583–12.18) 0.198
7/6 CC 11 (7.3%) 3 (4.8%) 2.09 (0.45–9.81) 0.343
7/6 CT 12 (8%) 4 (6.3%) 1.71 (0.41–7.14) 0.457
7/6 TT 6 (4%) 0 (0%) 7.62 (0.38–152.83) 0.080
6/6 CC 5 (3.3%) 2 (3.2%) 1.43 (0.22–9.14) 0.705
6/6 CT 8 (5.3%) 2 (3.2%) 2.28 (0.39–13.50) 0.355
6/6 TT 2 (1.3%) 0 (0%) 2.93 (0.12–68.55) 0.296
6/5 CC 13 (8.7%) 5 (7.9%) 1.49 (0.39–5.72) 0.564
6/5 CT 8 (5.3%) 1 (1.6%) 4.57 (0.48–43.50) 0.160
6/5 TT 2 (1.3%) 1 (1.6%) 1.14 (0.09–14.68) 0.918
7/5 CC 9 (6%) 9 (14.3%) 0.57 (0.16–2.03) 0.385
7/5 CT 15 (10%) 2 (3.2%) 4.29 (0.77–23.74) 0.081
7/5 TT 4 (2.7%) 5 (7.9%) 0.46 (0.09–2.21) 0.325
7/4 CC 3 (2%) 8 (12.7%) 0.21 (0.04–1.05) 0.048
7/4 CT 1 (0.7%) 0 (0%) 1.75 (0.06–48.19) 1.000
7/4 TT 2 (1.3%) 1 (1.6%) 1.14 (0.09–14.68) 0.918
5/5 CC 1 (0.7%) 2 (3.2%) 0.29 (0.02–3.67) 0.315
5/5 CT 3 (2%) 0 (0%) 4.10 (0.19–89.44) 0.205
6/4 CC 2 (1.3%) 2 (3.2%) 0.57 (0.07–4.87) 0.606
6/4 CT 1 (0.7%) 0 (0%) 1.75 (0.06–48.19) 1.000
5/4 CC 2 (1.3%) 1 (1.6%) 1.14 (0.09–14.68) 0.918
4/4 CC 0 (0%) 1 (1.6%) 0.19 (0.01–5.35) 0.202
8/5 CC 1 (0.7%) 0 (0%) 1.75 (0.06–48.19) 0.455
9/7 CC 1 (0.7%) 0 (0%) 1.75 (0.06–48.19) 0.455
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1.05, p 0.048) was observed, suggesting a possible link
between L-SIGN and IL28B genotypes in clearance of the virus.
Finally, to check the role of L-SIGN genotype 7/4 in the
prevalence of spontaneous HCV clearance, we stratiﬁed
subjects according to L-SIGN- 7/4 and IL28B-CC genotypes
(Fig. 2c). The result indicated that the prevalence of sponta-
neous clearance is higher (52.4%) among individuals with the
CC genotype without 7/4, followed by those carrying both CC
and 7/4 genotypes (12.7%).
Discussion
L-SIGN is a calcium-dependent carbohydrate-binding protein,
specialized in the recognition of carbohydrate structures
present on cellular and viral proteins and implicated in several
processes such as cell adhesion and antigen presentation
[15,24]. L-SIGN has been shown to act as a receptor with high-
afﬁnity-binding to hepatitis C virus glycoprotein E2 and may
facilitate transmission into adjacent hepatocytes [8–12]. The
neck region of the L-SIGN region plays a crucial role in the
tetramerization of the receptor and the support of CRDs, thus
inﬂuencing the pathogen-binding properties of these recep-
tors. The neck region of L-SIGN repeats is highly variable and
varies with ethnic groups [25]. Therefore, we ﬁrst examined
the frequency of this polymorphism in a Moroccan population
characterized by mixed Berberic and Arabic ethnicity as
determined by their geographical location between the
Mediterranean Sea, the Atlantic Ocean and the Sahara desert.
The frequency of heterozygosity for L-SIGN alleles was similar
in our Moroccan population (52.3%) to that reported in East
Asian populations (52%), Caucasian European populations
(61.5%) and Middle-Eastern populations (60.8%) [25], and the
frequency of heterozygotes was higher than that reported in
Chinese (45%) [17] and Japanese (37.4%) populations [26].
Allelic distribution of repeats in Moroccan individuals was
mostly represented by the wild-type 7-repeat form (56.4%),
followed by the 6- (20.2%), 5- (18.3%) and 4- alleles (5%). This
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FIG. 1. Analysis of virological, biochemical parameters and stage of disease in relation to L-SIGN. (a) Scatter plot and association of viral loads. ALT
and alleles in HCV-infected patients. (b) The mean AST levels stratiﬁed with respect to L-SIGN alleles and the results are shown as mean and SEM. (c)
AST levels according to L-SIGN and the results are shown as mean and SEM. (d) Distribution of L-SIGN variants in cirrhosis patients and healthy
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distribution is closer to that reported in Caucasian populations
[5,25,27]. The diversity of L-SIGN polymorphisms is due to
balancing selection in non-African populations [25]. However,
a recent study showed that demographic migration of different
tribes might also explain L-SIGN diversity [28].
In a large group of individuals from two combined cohorts it
has been demonstrated that the homozygous 7/7 genotype
was signiﬁcantly associated with an increased risk of HIV-1
infection (OR = 1.87, p 0.0015), with the heterozygous 7/5
genotype correlating with resistance to HIV-1 infection (OR =
0.69, p 0.029) [18]. This result was further conﬁrmed in
additional studies [19,29]. Moreover, a study on SARS patients
showed that individuals homozygous for L-SIGN neck-region
repeats were less susceptible to SARS-CoV infection
(OR = 0.649; p 0.005) [17]. However, these correlations
were not found in studies on HIV [30–32] or studies of
Mycobacterium tuberculosis infections [33]. The discrepancy
between these studies may be related to ethnic differences
between the different studies. A study, however, explored the
possible association between L-SIGN neck-region variation
and HCV infection using HCV-infected patients and healthy
controls. Although they did not ﬁnd a difference between
these two groups within the HCV population, they found that
individuals with the 4 and 9 alleles had lower viral loads, which
agrees well with our results [34].
Our study explores, for the ﬁrst time, the role of L-SIGN
neck-region variation in the clearance of HCV infection,
particularly the 7/4 genotype and 4- allele. The length variation
of this neck region had been proposed to affect the pathogen-
binding properties of the CRD of these proteins [15,24].
Moreover, in vitro studies show that cells with the L-SIGN-7
allele have higher levels of capture and trans-infection
decreased with progressive deletions of the tandem repeats
[20]. In addition, it has been reported that the number of
tandem repeats also inﬂuences binding afﬁnity for HIV-1 gp120
[35]. Recently, it has been shown that loss of neck repeats in
this variant reduces the extension of the CRDs from the
membrane surface, a feature that could reduce access to
pathogens [23]. These data indicate that L-SIGN isforms
thereby serve to modulate the outcome of HCV infection
and disease progression by inﬂuencing viral entry [20]. Inter-
estingly, our work suggests that variations in the number of L-
SIGN repeats were linked with HCV viraemia. Patients with 5-,
6- and 7-repeat alleles had higher HCV-RNA loads than
patients with the 4-repeat allele. This ﬁnding is consistent with a
previous report [34] highlighting the concept of trans-infection
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and capture of the HCV virus to infect adjacent hepatocyte cells
and HCV replication efﬁcacy were inﬂuenced by the L-SIGN
neck-region length. Furthermore, we found that variations in L-
SIGN genotypes/alleles were not associated with ALT and AST
levels, suggesting that this polymorphism was not involved in
hepatic inﬂammation and also there was no association with
viral genotype and treatment response. Indeed, this result was
conﬁrmed when we analysed the L-SIGN isoforms with the
progression of disease to cirrhosis. These preliminary data
indicate that L-SIGN neck region length polymorphism has no
affect on liver damage.
In summary, our data suggest that L-SIGN neck region
length polymorphism is associated with spontaneous clearance
of HCV and the replication efﬁciency of the hepatitis C virus.
Given the relatively small sample size in our study, future
studies of L-SIGN polymorphisms are warranted with larger
cohorts of individuals with diverse ethnic backgrounds.
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